A. H. Robins Company, Incorporated

Reevis S Alphin

Harry R Munson, Jr

William L Smith

William J Welstead, Jr

Carl D Lunsford

Lina C Teng

Robert F Boswell

John Wesley Ward

Lennox B Turnbull

Stephen C Bearekman

David Andrew Droppleman

A method of controlling emesis caused by anticancer drugs with 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamide-N-oxides having the formula: ##STR1## wherein R.sub.1 is loweralkyl, and R.sub.2 is selected from the group consisting of hydrogen, halo, 4,5-benzo, methylsulfonyl, loweralkoxy or Am and n is 1 or 2, and the pharmaceutically acceptable acid addition salts thereof is disclosed.

Method of using

A method of controlling emesis caused by non-platinum anti-cancer drugs with 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides having the formula ##STR1## wherein X is oxygen or sulfur; R.sub.1 is loweralkyl; and R.sub.2 is selected from the group consisting of hydrogen, halo, 4,5-benzo, methylsulfonyl, loweralkoxy or Am and n is 1 or 2, and the pharmaceutically acceptable acid addition salts thereof is disclosed.

2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides

A method of reducing gastric acidity and treating peptic ulcers and pharmaceutical compositions therefor with certain 4-amino-3-quinolinecarboxylic acids and esters are disclosed. Illustrative of compounds useful in the method which relies on activity as antisecretory activity is the novel compound ethyl 8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinecarboxylate which has the formula: ##STR1##

4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer

Pyrrolidinyl benzamides represented by the formula: ##STR1## wherein R is methyl or cycloalkyl having 3 to 12 carbon atoms; R.sup.1 is hydrogen or methyl and the pharmaceutically acceptable salts thereof are disclosed in methods which increase the rate of gastric emptying in mammals.

Method of increasing rate of gastric emptying with pyrrolidinylbenzamides

Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenoxy- and substituted-phenoxy alcohols, carbamates, aminoalcohols, carbamoylalcohols, oxazolidinones, pyrrolidines, thiosemicarbazides and aminoalkylacetamides. The compounds act systemically to ameliorate gastric bleeding otherwise caused by aspirin.

Phenoxy compounds in combinations to suppress gastric bleeding in

Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenylalkylamines and phenylalkylureas having the formula: ##STR1## wherein Z is selected from the group consisting of --NHR.sup.2 or ##STR2## and R is selected from the group consisting of hydrogen, halogen, lower-alkoxy and trifluoromethyl and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen and lower-alkyl, where R.sup.3 and R.sup.4 taken together with the adjacent nitrogen atom may form a heterocyclic ring selected from the group of piperidino, pyrrolidino, piperazino, and morpholino.

Phenylalkylamines and phenylalkylureas in combinations to suppress

Methods of treating symptomatic conditions of inflammation due to chronic and acute rheumatic and degenerative joint disease with a combination of indomethacin or phenylbutazone and a phenoxymethyl-2-oxazolidinone resulting in beneficial reduction in side effects of ulceration and bleeding in the lower intestinal tract normally associated with indomethacin and phenylbutazone and compositions containing the combination are disclosed.

Growing community of inventors

Richmond, VA, United States of America

Reevis S Alphin